Worth Venture Partners’s Immunogen Inc IMGN Stock Holding History

Worth Venture Partners’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-156,200	Closed	-$172K	–	182
2023 Q3	$172K	Buy	156,200 +45,600	+41%	+$758K	0.1%	109
2023 Q2	$72.3K	Buy	+110,600	New	+$1.31M	0.04%	138
2023 Q1	–	Sell	-25,500	Closed	-$3.83K	–	218
2022 Q4	$3.83K	Buy	+25,500	New	+$138K	﹤0.01%	167

Other funds holding IMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Worth Venture Partners's IMGN Position: Q2 2019 in Review

Worth Venture Partners sold out of Immunogen Inc (IMGN) in Q2 2019, closing a stake of 53,382 shares — an estimated $145K sold.

Worth Venture Partners first reported a position in IMGN in Q1 2019 and held it in 1 quarter. The position peaked at $145K in Q1 2019. 192 funds tracked by Wall St. Rank hold IMGN as of Q2 2019.

Worth Venture Partners reported no remaining Immunogen Inc position as of Q2 2019 after selling out during the quarter.
Worth Venture Partners sold 53,382 Immunogen Inc shares in Q2 2019, an estimated $145K.
Worth Venture Partners first reported a position in Immunogen Inc in Q1 2019 and held it in 1 quarter.
Worth Venture Partners's Immunogen Inc position peaked at $145K in Q1 2019.
192 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2019.

Based on Worth Venture Partners's 13F filing for Q2 2019, filed 14 Aug 2019.